GeneQuantum Healthcare (Suzhou) Co., Ltd. Report issue

For profit Phase 1 Phase 2
Founded: Suzhou China (2013)

Organization Overview

First Clinical Trial
2020
NCT04450732
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (3)

capecitabine (xeloda) (1 trial)

gq1001 (2 trials)

pyrotinib (1 trial)

Drugs in Phase 1 Trials (1)

gq1005 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4